September 30 - October 2, 2021   Virtual Event

Non-CME Educational Activities

All events are scheduled during times that do not conflict with Symposium CME educational programing.

These optional non-CME educational activity are not approved for CME or continuing education credit. The content of these optional non-CME activities and opinions expressed by presenters are those of the sponsor or presenters.

All times listed are Central Time Zone.


TUKYSA® (tucatinib): Clinical Trial Data

Thursday, September 30, 2021 • 11:40 a.m. – 12:40 p.m.

Sponsored by Seagen
For more information contact Mona Powell (rpowell@seagen.com)


Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer

Thursday, September 30, 2021 • 3:20 p.m. – 4:20 p.m.

Sponsored by Gilead Sciences, Inc.
For more information contact gileadsciences-events@pharmethod.com


Clinical Trial Evidence for CDK4/6 Inhibitor Combination Therapy Complemented by an Evaluation of Real-World Effectiveness

Friday, October 1, 2021 • 8:00 a.m. – 8:45 a.m.

Sponsored by Pfizer


A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely To Do Worse

Friday, October 1, 2021 • 12:00 p.m. – 1:00 p.m.

Sponsored by Lilly


Combining the HER2+ Breast Cancer Antibodies You Know in One Faster Mode of Administration

Saturday, October 2, 2021 • 12:00 p.m. – 1:00 p.m.

Sponsored by Genentech
For more information contact Lynn Dworzanin (Dworzanin.lynn@gene.com)

© 2021 Robert H. Lurie Comprehensive Cancer Center